Ikarian Capital LLC recently announced the acquisition of new stake in Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP). The institutional investor has increased its shareholding in the Healthcare company by 1.89% to 0.2 million shares with purchase of 3639.0 shares. This fresh investment now brings its stake to 4.43% valued currently at $1.18 million. In addition, Boothbay Fund Management LLC raised its holdings by 3639.0 to 41615.0 shares. And Geode Capital Management LLC has lifted its position by 13.13% or 4316.0 shares – to 37181.0 shares.
Currently, there are 4.42M common shares owned by the public and among those 4.41M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Corbus Pharmaceuticals Holdings Inc are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market ETF owns 0.11 million shares of the company’s stock, all valued at over $0.68 million. Fidelity Extended Market Index Fu now owns shares totaling to 0.52% of the shares outstanding.
However, the script later moved the day high at 39.96, up 249.41%. The company’s stock has a 5-day price change of 318.30% and 415.56% over the past three months. CRBP shares are trading 388.25% year to date (YTD), with the 12-month market performance up to 614.91% higher. It has a 12-month low price of $2.11 and touched a high of $13.17 over the same period. CRBP has an average intraday trading volume of 25.97K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 343.44%, 413.12%, and 318.24% respectively.
Institutional ownership of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) shares accounts for 16.85% of the company’s 4.42M shares outstanding. Mutual fund holders own 10.93%, while other institutional holders and individual stakeholders account for 5.93% and 0.05% respectively.
It has a market capitalization of $130.35M and a beta (3y monthly) value of 2.35. The earnings-per-share (ttm) stands at -$11.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 41.40% over the week and 17.34% over the month.
Analysts forecast that Corbus Pharmaceuticals Holdings Inc (CRBP) will achieve an EPS of -$2.5 for the current quarter, -$1.52 for the next quarter and -$6.59 for 2024. The lowest estimate earnings-per-share for the quarter is -$2.5 while analysts give the company a high EPS estimate of -$2.5. Comparatively, EPS for the current quarter was -$2.61 a year ago. Earnings per share for the fiscal year are expected to decrease by -8.37%, and 40.09% over the next financial year.
Looking at the support for the CRBP, a number of firms have released research notes about the stock. ROTH Capital stated their Neutral rating for the stock in a research note on September 08, 2020, with the firm’s price target at $40-$3.
